tiprankstipranks
Trending News
More News >
Generation Bio Co. (GBIO)
NASDAQ:GBIO
US Market
Advertisement

Generation Bio (GBIO) AI Stock Analysis

Compare
221 Followers

Top Page

GBIO

Generation Bio

(NASDAQ:GBIO)

Rating:46Neutral
Price Target:
$0.50
▼(-88.10%Downside)
Generation Bio's overall score is primarily influenced by its financial performance, which highlights strong revenue growth but significant profitability challenges. Technical analysis shows some positive momentum, but valuation is hampered by negative earnings. The absence of earnings call and corporate events data limits additional insights.
Positive Factors
Financial Stability
Cash runway is expected to fund operations into the second half of 2027, providing financial stability for ongoing projects.
Market Position
Generation Bio Co. is focusing on innovative siRNA therapeutics for autoimmune disorders, which could set them apart in the market.
Technological Innovation
Successfully delivering mRNA directly into T-cells could differentiate Generation Bio Co. from competitors, who primarily target the liver.
Negative Factors
Regulatory Concerns
FDA/NIH changes may present a long-term challenge due to the significant uncertainty they introduce.
Stock Valuation
The stock is currently trading below its cash position, which is viewed as a fair discount consistent with other biotech companies with similar uncertainties.

Generation Bio (GBIO) vs. SPDR S&P 500 ETF (SPY)

Generation Bio Business Overview & Revenue Model

Company DescriptionGeneration Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
How the Company Makes MoneyGeneration Bio makes money through the development and potential commercialization of its proprietary gene therapy platforms. The company's primary revenue streams are expected to come from partnerships with other biotechnology and pharmaceutical companies, as well as potential licensing agreements. These partnerships may involve collaborative research, co-development of therapies, and milestone payments associated with successful development stages. Additionally, Generation Bio may generate revenue from royalties on sales of successfully commercialized therapies developed through its platform. The company's strategic focus on innovation and collaboration in the gene therapy space is crucial for its financial sustainability and growth.

Generation Bio Financial Statement Overview

Summary
Generation Bio exhibits substantial revenue growth with a Revenue Growth Rate of 23.45%, but faces severe profitability issues as shown by a negative Net Profit Margin of -292.83%. The balance sheet displays moderate leverage with a Debt-to-Equity Ratio of 1.19, yet declining financial stability with an Equity Ratio of 36.41%. Cash flows are improving but remain negative, indicating ongoing operational challenges.
Income Statement
40
Negative
The company's revenue has shown significant growth, particularly in the latest TTM period, with a Revenue Growth Rate of 23.45% from the previous year. Despite this, Generation Bio is struggling with profitability, as evidenced by a negative Net Profit Margin (-292.83%) and negative EBIT and EBITDA margins. The gross profit margin for the most recent TTM is positive at 100%, indicating that all revenues are above the cost of goods sold, but the high operating expenses are leading to substantial losses.
Balance Sheet
45
Neutral
Generation Bio's balance sheet shows a moderate level of stability. The Debt-to-Equity Ratio is 1.19, indicating moderate leverage. However, the Equity Ratio has been decreasing, currently at 36.41%, highlighting a reduction in financial stability. Return on Equity remains negative due to ongoing net losses, indicating that shareholders' equity is not generating positive returns.
Cash Flow
50
Neutral
Cash flow analysis reveals challenges with negative free cash flow, though the Free Cash Flow to Net Income Ratio is improving. The company has a high Operating Cash Flow to Net Income Ratio of 1.19, suggesting that operating cash flows are relatively strong compared to net income losses. Free Cash Flow Growth Rate is positive, indicating some improvement in cash management.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue19.89M5.90M0.000.000.00
Gross Profit19.89M-73.91M-5.13M-4.53M-3.43M
EBITDA-74.26M-133.30M-136.05M-114.57M-77.68M
Net Income-131.67M-126.61M-132.10M-114.67M-76.50M
Balance Sheet
Total Assets231.20M374.76M376.26M476.77M294.15M
Cash, Cash Equivalents and Short-Term Investments185.22M264.36M279.09M375.14M262.33M
Total Debt93.56M97.89M81.71M80.83M0.00
Total Liabilities144.99M171.63M93.77M95.03M26.14M
Stockholders Equity86.20M203.13M282.49M381.75M268.01M
Cash Flow
Free Cash Flow-90.96M-60.14M-111.25M-97.78M-75.66M
Operating Cash Flow-88.56M-52.74M-102.45M-91.82M-70.14M
Investing Cash Flow94.53M-9.70M-192.51M193.05M-205.20M
Financing Cash Flow250.00K35.82M12.99M214.67M323.10M

Generation Bio Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price4.20
Price Trends
50DMA
3.88
Positive
100DMA
4.13
Positive
200DMA
8.99
Negative
Market Momentum
MACD
0.18
Negative
RSI
51.98
Neutral
STOCH
24.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GBIO, the sentiment is Neutral. The current price of 4.2 is above the 20-day moving average (MA) of 3.93, above the 50-day MA of 3.88, and below the 200-day MA of 8.99, indicating a neutral trend. The MACD of 0.18 indicates Negative momentum. The RSI at 51.98 is Neutral, neither overbought nor oversold. The STOCH value of 24.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GBIO.

Generation Bio Risk Analysis

Generation Bio disclosed 82 risk factors in its most recent earnings report. Generation Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Generation Bio Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
57
Neutral
$268.10M-414.88%-65.96%40.80%
50
Neutral
AU$2.62B3.32-57.47%2.40%36.73%13.67%
50
Neutral
$23.54M597.53%88.13%92.45%
46
Neutral
$29.03M-70.06%146.47%57.85%
44
Neutral
$17.88M-83.73%42.39%
41
Neutral
$49.90M-161.93%-0.38%
30
Underperform
$48.70M-2880.11%31.09%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GBIO
Generation Bio
4.20
-30.00
-87.72%
TVRD
Tvardi Therapeutics
27.29
14.15
107.69%
DARE
Daré Bioscience
2.63
-0.97
-26.94%
PASG
Passage Bio
5.73
-11.87
-67.44%
CGTX
Cognition Therapeutics
0.86
-1.24
-59.05%
NRSN
Neurosense Therapeutics Ltd.
2.03
1.22
150.62%

Generation Bio Corporate Events

Delistings and Listing ChangesStock Split
Generation Bio Announces Reverse Stock Split
Neutral
Jul 18, 2025

On July 18, 2025, Generation Bio announced a 1-for-10 reverse stock split of its common stock, effective July 21, 2025, to comply with Nasdaq’s minimum bid price requirement. This move will reduce the company’s outstanding shares from approximately 67.3 million to 6.7 million, with trading on a split-adjusted basis starting July 22, 2025.

The most recent analyst rating on (GBIO) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Generation Bio stock, see the GBIO Stock Forecast page.

Executive/Board ChangesShareholder MeetingsStock Split
Generation Bio Elects Directors and Approves Key Proposals
Neutral
Jun 5, 2025

On June 4, 2025, Generation Bio Co. conducted its annual meeting of stockholders, where key proposals were voted upon. The meeting resulted in the election of Ron Cooper, Anthony Quinn, and Jason Rhodes as Class II directors, ratification of Ernst & Young LLP as the independent auditor, approval of executive compensation, and authorization of a reverse stock split amendment.

The most recent analyst rating on (GBIO) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Generation Bio stock, see the GBIO Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 19, 2025